Published in J Exp Med on February 17, 1997
Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother (1998) 2.74
The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol (2009) 1.97
Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev (1998) 1.82
Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection. Infect Immun (1998) 1.63
Phenotypic switching in Cryptococcus neoformans results in changes in cellular morphology and glucuronoxylomannan structure. Infect Immun (1999) 1.60
Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect Immun (2005) 1.42
The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays. Clin Diagn Lab Immunol (1998) 1.37
The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response. Infect Immun (2007) 1.30
Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect Immun (2002) 1.24
Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule. Infect Immun (1998) 1.19
Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection. Infect Immun (2007) 1.17
Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J Clin Invest (2010) 1.16
Antibody interactions with the capsule of Cryptococcus neoformans. Infect Immun (2000) 1.10
Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Infect Immun (2004) 1.06
Phenotypic switching in a Cryptococcus neoformans variety gattii strain is associated with changes in virulence and promotes dissemination to the central nervous system. Infect Immun (2006) 1.05
Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen. Infect Immun (2004) 0.98
Immunomodulatory effects of serotype B glucuronoxylomannan from Cryptococcus gattii correlate with polysaccharide diameter. Infect Immun (2010) 0.98
Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice. Infect Immun (2004) 0.97
Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and nonprotective antibodies. Infect Immun (2001) 0.93
Passive administration of monoclonal antibodies to anthrolysin O prolong survival in mice lethally infected with Bacillus anthracis. BMC Microbiol (2008) 0.93
Loss of allergen 1 confers a hypervirulent phenotype that resembles mucoid switch variants of Cryptococcus neoformans. Infect Immun (2008) 0.92
Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan. Clin Vaccine Immunol (2008) 0.91
Antibodies produced in response to Cryptococcus neoformans pulmonary infection in mice have characteristics of nonprotective antibodies. Infect Immun (2004) 0.87
Antibody binding to Cryptococcus neoformans impairs budding by altering capsular mechanical properties. J Immunol (2012) 0.87
The protective role of immunoglobulins in fungal infections and inflammation. Semin Immunopathol (2014) 0.85
Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis. Vaccine (2011) 0.83
Effect of human immunodeficiency virus infection on plasma bactericidal activity against Salmonella enterica serovar Typhimurium. Clin Vaccine Immunol (2014) 0.83
Role of the Apt1 protein in polysaccharide secretion by Cryptococcus neoformans. Eukaryot Cell (2013) 0.83
Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays. Infect Immun (2013) 0.83
Strain-related differences in antibody-mediated changes in gene expression are associated with differences in capsule and location of binding. Fungal Genet Biol (2012) 0.82
In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies. Infect Immun (1999) 0.82
Monoclonal antibody 13F1 produces annular immunofluorescence patterns on Cryptococcus neoformans serotype AD isolates. J Clin Microbiol (1999) 0.80
Host defence to pulmonary mycosis. Can J Infect Dis (1999) 0.80
Bivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule. Infect Immun (1998) 0.79
An opsonizing monoclonal antibody that recognizes a noncapsular epitope expressed on Cryptococcus neoformans. Infect Immun (1999) 0.79
Peptide mimic of phosphorylcholine, a dominant epitope found on Streptococcus pneumoniae. Infect Immun (2000) 0.78
Fungal vaccines and immunotherapeutics. Cold Spring Harb Perspect Med (2014) 0.77
Cryptococcus neoformans glucuronoxylomannan fractions of different molecular masses are functionally distinct. Future Microbiol (2014) 0.76
The Cryptococcus neoformans capsule: lessons from the use of optical tweezers and other biophysical tools. Front Microbiol (2015) 0.75
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Searching for peptide ligands with an epitope library. Science (1990) 10.75
Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect Immun (1972) 4.45
Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene (1988) 4.14
Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol (1993) 4.10
Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun (1992) 3.21
Capsular polysaccharides of Cryptococcus neoformans. Rev Infect Dis (1984) 3.10
Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis (1992) 2.98
Monoclonal antibody based ELISAs for cryptococcal polysaccharide. J Immunol Methods (1992) 2.97
Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis (1994) 2.87
Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun (1987) 2.63
The importance of the location of antibody binding on the M6 protein for opsonization and phagocytosis of group A M6 streptococci. J Exp Med (1988) 2.42
Antibody response that protects against disseminated candidiasis. Infect Immun (1995) 2.31
Antibody immunity and invasive fungal infections. Infect Immun (1995) 2.31
Localization on encapsulated Cryptococcus neoformans of serum components opsonic for phagocytosis by macrophages and neutrophils. Infect Immun (1984) 2.30
The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies. J Exp Med (1991) 2.11
Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med (1995) 2.11
Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med (1993) 2.09
Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun (1995) 2.09
Role of the capsule in phagocytosis of Cryptococcus neoformans. Rev Infect Dis (1988) 2.03
Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect Immun (1995) 1.70
The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol (1991) 1.68
Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J Immunol (1995) 1.67
Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet (1992) 1.67
Karyotype instability in Cryptococcus neoformans infection. J Clin Microbiol (1996) 1.53
J774 murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins. J Infect Dis (1996) 1.51
Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans. J Mol Biol (1996) 1.41
Activation of the complement system by pathogenic fungi. Clin Microbiol Rev (1996) 1.37
Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion. Infect Immun (1995) 1.31
Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans. J Exp Med (1996) 1.19
Virus sensitization. Curr Top Microbiol Immunol (1972) 1.17
Synthesis of complement by macrophages and modulation of their functions through complement activation. Springer Semin Immunopathol (1983) 1.10
Enhancement of ELISAs for screening peptides in epitope phage display libraries. J Immunol Methods (1996) 0.84
The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology (1968) 7.42
A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet (1977) 5.65
Synthesis, assembly, and secretion of gamma globulin by mouse myeloma cells. I. Adaptation of the Merwin plasma cell tumor-11 to culture, cloning, and characterization of gamma globulin subunits. J Exp Med (1970) 4.26
The polypeptides of adenovirus. II. Soluble proteins, cores, top components and the structure of the virion. Virology (1968) 4.19
Rapidly labeled, polyribosome-associated RNA having the properties of histone messenger. Proc Natl Acad Sci U S A (1967) 4.12
Rate of somatic mutation in immunoglobulin production by mouse myeloma cells. Proc Natl Acad Sci U S A (1971) 3.83
Preparation of mammalian polyribosomes with the detergent Nonidet P-40. Biochim Biophys Acta (1967) 3.81
Use of monoclonal anti-mouse immunoglobulin to detect mouse antibodies. Hybridoma (1981) 3.58
Urease as a virulence factor in experimental cryptococcosis. Infect Immun (2000) 3.53
Polyribosomal synthesis and assembly of the H and L chains of gamma globulin. Proc Natl Acad Sci U S A (1966) 3.53
Cryptococcus neoformans melanin and virulence: mechanism of action. Infect Immun (1995) 3.43
Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect Immun (2000) 3.42
Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol (1999) 3.38
Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci U S A (2001) 3.37
Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity. Proc Natl Acad Sci U S A (1984) 3.35
Intracellular parasitism of macrophages by Cryptococcus neoformans. Trends Microbiol (2001) 3.34
Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet (1993) 3.34
Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun (1992) 3.21
Somatic cell hybridization of mouse myeloma cells. Cell (1976) 3.17
Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol (2001) 3.02
Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis (1992) 2.98
Monoclonal antibody based ELISAs for cryptococcal polysaccharide. J Immunol Methods (1992) 2.97
Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis (1994) 2.87
Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother (1998) 2.74
Cloning of mouse myeloma cells and detection of rare variants. J Cell Physiol (1972) 2.63
The role of somatic hypermutation in the generation of antibody diversity. Science (1989) 2.55
Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical sources in New York City. J Clin Microbiol (1994) 2.43
Susceptibility of melanized and nonmelanized Cryptococcus neoformans to nitrogen- and oxygen-derived oxidants. Infect Immun (1994) 2.41
Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics (2001) 2.40
The Fc receptors of primary and cultured phagocytic cells studied with homogeneous antibodies. J Immunol (1978) 2.38
Synthesis and assembly of adenovirus 2. I. Polypeptide synthesis, assembly of capsomeres, and morphogenesis of the virion. Virology (1969) 2.27
Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. J Immunol (1997) 2.25
Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure. J Clin Microbiol (1997) 2.19
Melanin, melanin "ghosts," and melanin composition in Cryptococcus neoformans. Infect Immun (1996) 2.15
A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci U S A (1998) 2.13
Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect Immun (1998) 2.12
The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies. J Exp Med (1991) 2.11
Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med (1995) 2.11
Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med (1993) 2.09
Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun (1995) 2.09
Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology (2001) 2.08
Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun (1994) 2.07
Extensive allelic variation in Cryptococcus neoformans. J Clin Microbiol (1992) 2.06
Antigen-binding mutants of mouse myeloma cells. Proc Natl Acad Sci U S A (1977) 2.04
The role of somatic mutation in the pathogenic anti-DNA response. Annu Rev Immunol (1992) 2.02
Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother (1994) 2.00
Mutations in immunoglobulin-producing mouse myeloma cells. Science (1973) 1.94
Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother (1997) 1.89
Variants of a mouse myeloma cell line that synthesize immunoglobulin heavy chains having an altered serotype. Proc Natl Acad Sci U S A (1975) 1.87
Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc Natl Acad Sci U S A (1993) 1.86
Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis (1995) 1.86
Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immun (1994) 1.83
Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev (1998) 1.82
Somatic hypermutation in MutS homologue (MSH)3-, MSH6-, and MSH3/MSH6-deficient mice reveals a role for the MSH2-MSH6 heterodimer in modulating the base substitution pattern. J Exp Med (2000) 1.82
Immunoglobulin production: method for quantitatively detecting variant myeloma cells. Science (1970) 1.81
Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect Immun (1995) 1.79
Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents. Infect Immun (2000) 1.79
Lymphoblastoid cell lines from patients with chronic lymphocytic leukemia: identification of tumor origin by idiotypic analysis. Proc Natl Acad Sci U S A (1978) 1.78
The polypeptides of adenovirus. 3. Synthesis in infected cells. Virology (1969) 1.77
Monoclonal antibodies to surface antigens of Mycobacterium tuberculosis and their use in a modified enzyme-linked immunosorbent spot assay for detection of mycobacteria. J Clin Microbiol (1996) 1.76
Heavy chain-producing variants of a mouse myeloma cell line. J Immunol (1975) 1.73
T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc Natl Acad Sci U S A (1997) 1.72
Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C. neoformans. Genes Dev (2001) 1.72
Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications. Hum Pathol (1996) 1.71
Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect Immun (1995) 1.70
Cellular charge of Cryptococcus neoformans: contributions from the capsular polysaccharide, melanin, and monoclonal antibody binding. Infect Immun (1997) 1.69
Synthesis of ribosomal RNA in synchronized HeLa cells. Nature (1965) 1.69
Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J Immunol (1995) 1.67
Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet (1992) 1.67
Synthesis of excess light chains of gamma globulin by rabbit lymph node cells. Nature (1966) 1.66
Variants of mouse myeloma cells that produce short immunoglobulin heavy chains. Proc Natl Acad Sci U S A (1974) 1.66
Decreased susceptibility of melanized Cryptococcus neoformans to UV light. Appl Environ Microbiol (1994) 1.65
Laccase of Cryptococcus neoformans is a cell wall-associated virulence factor. Infect Immun (2001) 1.64
Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection. Infect Immun (1998) 1.63
Polyribosome disaggregation during metaphase. Science (1966) 1.61
Effect of adenovirus on host cell DNA synthesis in synchronized cells. Virology (1969) 1.61
Nucleic acid and protein sequences of phosphocholine-binding light chains. J Exp Med (1981) 1.61
Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc Natl Acad Sci U S A (1997) 1.61
Phenotypic switching in Cryptococcus neoformans results in changes in cellular morphology and glucuronoxylomannan structure. Infect Immun (1999) 1.60
Two kappa immunoglobulin genes are expressed in the myeloma S107. Cell (1981) 1.60
Melanization of Cryptococcus neoformans in murine infection. Mol Cell Biol (1999) 1.59
Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents. Proc Natl Acad Sci U S A (1998) 1.58
Radiological studies reveal radial differences in the architecture of the polysaccharide capsule of Cryptococcus neoformans. Eukaryot Cell (2005) 1.58
Synthesis of a carboxyl-terminal (constant region) fragment of the immunoglobulin light chain by a mouse myeloma cell line. J Mol Biol (1974) 1.54
Karyotype instability in Cryptococcus neoformans infection. J Clin Microbiol (1996) 1.53
Growth of Cryptococcus neoformans in presence of L-dopa decreases its susceptibility to amphotericin B. Antimicrob Agents Chemother (1994) 1.53
Molecular epidemiology of clinical Cryptococcus neoformans strains from India. J Clin Microbiol (2005) 1.53
J774 murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins. J Infect Dis (1996) 1.51